Showing all publications

Pages

Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

Baxter JD; Dunn D; White E; Sharma S; Geretti AM; Kozal MJ; Johnson MA; Jacoby S; Llibre JM; Lundgren J.
, 2015.

Age-specific and sex-specific weight gain norms to monitor antiretroviral therapy in children in low-income and middle-income countries.

Yotebieng M; Meyers T; Behets F; Davies MA; Keiser O; Ngonyani KZ; Lyamuya RE; Kariminia A; Hansudewechakul R; Leroy V; Koumakpai S; Newman J; Van Rie A.
, 2015.

Is it time to rethink syphilis control?

Boyd MA; Donovan B; Prestage G; Chen M; Petoumenos K; Gray R; Guy R; Rogers GB; Bourne C; Klausner JD.
, 2015.

Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC(3) study.

Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J.
, 2015.

Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

Soliman EZ; Sharma S; Arastéh K; Wohl D; Achhra A; Tambussi G; O'Connor J; Stein JH; Duprez DA; Neaton JD; Phillips A.
, 2015.

A new approach to estimating trends in chlamydia incidence.

Ali H; Cameron E; Drovandi CC; McCaw JM; Guy RJ; Middleton M; El-Hayek C; Hocking JS; Kaldor JM; Donovan B; Wilson DP.
, 2015.

Pages